Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".
作者信息
Dhakal Sandesh
机构信息
College of Medical Sciences, Bharatpur, Chitwan, Nepal.
出版信息
Heart Lung. 2023 Mar-Apr;58:256-257. doi: 10.1016/j.hrtlng.2022.09.004. Epub 2022 Sep 14.
Abstract
摘要
相似文献
1
Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".关于“新冠疫情下院前抗血小板药物使用对疾病严重程度的影响”的评论
Heart Lung. 2023 Mar-Apr;58:256-257. doi: 10.1016/j.hrtlng.2022.09.004. Epub 2022 Sep 14.
2
Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".关于“院前使用抗血小板药物对新冠病毒疾病严重程度的影响”的评论
Heart Lung. 2022 Sep-Oct;55:164-165. doi: 10.1016/j.hrtlng.2022.04.020. Epub 2022 May 2.
3
Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021).美国医院在 COVID-19 大流行前后（2018-2021 年）抗凝和抗血小板药物供应的变化。
Am J Health Syst Pharm. 2023 May 24;80(11):692-698. doi: 10.1093/ajhp/zxac381.
4
Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow® be used as an antiplatelet regime?在 COVID-19 中血小板过度活跃：番茄提取物 Fruitflow®能否用作抗血小板治疗？
Med Hypotheses. 2021 Feb;147:110480. doi: 10.1016/j.mehy.2020.110480. Epub 2021 Jan 4.
5
Effects of Pre-Hospital Antiplatelet Therapy on the Incidence of ARDS.院前抗血小板治疗对 ARDS 发生率的影响。
Respir Care. 2020 Jul;65(7):1039-1045. doi: 10.4187/respcare.07177. Epub 2020 Feb 11.
6
Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis.COVID-19 住院患者中院前抗血小板治疗与生存的关系：倾向评分匹配分析。
J Thromb Haemost. 2021 Nov;19(11):2814-2824. doi: 10.1111/jth.15517. Epub 2021 Sep 15.
7
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.抗血小板治疗在 COVID-19 大流行前后急性冠状动脉综合征患者中的有效性及其影响因素。
Medicina (Kaunas). 2022 Dec 30;59(1):84. doi: 10.3390/medicina59010084.
8
Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation.血小板活化与 2019 年冠状病毒病死亡率：从凝血异常、抗血小板治疗和炎症中获得的见解。
Arch Cardiovasc Dis. 2023 Apr;116(4):183-191. doi: 10.1016/j.acvd.2023.01.006. Epub 2023 Feb 14.
9
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study.联合抗凝和抗血小板治疗与 COVID-19 住院患者的改善结局相关：一项倾向评分匹配队列研究。
Open Heart. 2021 Oct;8(2). doi: 10.1136/openhrt-2021-001785.
10
Antiplatelet Therapy in Patients With COVID-19-More Is Less?新冠病毒肺炎患者的抗血小板治疗——多即少？
JAMA. 2022 Jan 18;327(3):223-224. doi: 10.1001/jama.2021.23866.
本文引用的文献
1
Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.抗血小板治疗与 COVID-19 结局：健康结局预测评估登记。
Heart. 2022 Jan;108(2):130-136. doi: 10.1136/heartjnl-2021-319552. Epub 2021 Oct 5.
2
Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis.COVID-19 住院患者中院前抗血小板治疗与生存的关系：倾向评分匹配分析。
J Thromb Haemost. 2021 Nov;19(11):2814-2824. doi: 10.1111/jth.15517. Epub 2021 Sep 15.
3
Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review.COVID-19 治疗中联合使用抗凝和抗血小板药物的作用：快速综述。
Open Heart. 2021 Jun;8(1). doi: 10.1136/openhrt-2021-001628.
4
Pre-hospital antiplatelet medication use on COVID-19 disease severity.COVID-19 疾病严重程度与院前抗血小板药物的使用。
Heart Lung. 2021 Sep-Oct;50(5):618-621. doi: 10.1016/j.hrtlng.2021.04.010. Epub 2021 May 27.
5
The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.抗血小板药物在新型冠状病毒肺炎动脉血栓预防中的应用。
Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):114-115. doi: 10.1016/j.rec.2020.08.009. Epub 2020 Aug 28.
Zotero 插件